Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 166

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cryoablation and Hepatic Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab for the Treatment of Locally Advanced or Metastatic and/or Unresectable Liver cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Chemoimmunotherapy Combined with Deep Hyperthermia and Spatially-fractionated Radiotherapy for the Treatment of Advanced Biliary Tract Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Treating Fields Therapy in Combination with Chemotherapy for the Treatment of Advanced Solid Tumors Involving the Abdomen or Thorax
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Status: Active
Location: See ClinicalTrials.gov
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Location: See ClinicalTrials.gov
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study of ZW251 in Participants With Advanced Solid Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: See ClinicalTrials.gov
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Status: Active
Location: See ClinicalTrials.gov
A Radioactive Drug (177Lu–PSMA-617) for the Treatment of PSMA Positive Metastatic and/or Unresectable Liver Cancer
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee